

SQ HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (terminated appraisal)

Technology appraisal guidance

Published: 12 October 2022

www.nice.org.uk/guidance/ta834

Contents

| | |
|------------------|---|
| Advice..... | 3 |
| Information..... | 3 |

Advice

NICE is unable to make a recommendation about the use in the NHS of SQ HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites. This is because ALK-Abello has confirmed that it does not intend to provide an evidence submission. ALK-Abello considers that it is essential to collect more clinical evidence to make a comprehensive and robust submission.

Information

If NHS organisations wish to consider SQ HDM SLIT for this indication, they should follow the advice on rational local decision making in the [NHS Constitution for England](#) and the [NHS Commissioning Board and Clinical Commissioning Groups \(Responsibilities and Standing Rules\) Regulations 2012](#). This outlines the approach that should be taken when there is no NICE guidance.

NICE will review the position if the company decides that it wants to make an evidence submission.

ISBN: 978-1-4731-4781-2